
Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1092 | 975 | 1092 | 1046 | 1217 | - |
Fund Return | 9.19% | -2.54% | 9.19% | 1.5% | 4.01% | - |
Place in category | 54 | 24 | 54 | 23 | 134 | - |
% in Category | 9 | 4 | 9 | 4 | 30 | - |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
UBS CH Institutional Fund 2 EquiP2X | 8.39B | -0.94 | 10.99 | 12.14 | ||
UBS CH Institutional Fund 2 EquiPAX | 4.37B | 0.81 | 9.73 | 9.73 | ||
UBS CH Vitainvest 50 World U | 4.31B | 7.32 | -1.50 | 2.35 | ||
UBS CH Institutional Fund 2 EquiSCX | 2.87B | 3.63 | 3.95 | 8.17 | ||
UBS CH Institutional Fund 2 EquiSCB | 2.87B | 3.63 | 3.89 | 8.11 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
CH0033782431 | 2.73B | 11.69 | 5.78 | 7.07 | ||
Pictet CH Institutional Swiss EquiZ | 2.29B | 8.90 | 2.54 | 8.57 | ||
Pictet CH Institutional Swiss EquiI | 2.29B | 8.86 | 2.05 | 8.05 | ||
Pictet CH Institutional Swiss EquZD | 2.29B | 10.09 | 3.81 | 7.80 | ||
Pictet CH Institutional Swiss EquiP | 2.29B | 8.84 | 1.85 | 7.84 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Nestle | CH0038863350 | 9.50 | 88.60 | -2.10% | |
Novartis | CH0012005267 | 9.22 | 95.70 | -5.60% | |
UBS Group | CH0244767585 | 9.04 | 27.66 | -2.64% | |
Roche Holding Participation | CH0012032048 | 9.03 | 296.50 | -3.55% | |
Zurich Insurance Group | CH0011075394 | 8.87 | 592.80 | -1.53% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Neutral |
Technical Indicators | Neutral | Strong Buy | Strong Buy |
Summary | Neutral | Strong Buy | Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review